These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11807713)

  • 1. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.
    Deeks SG; Hoh R; Grant RM; Wrin T; Barbour JD; Narvaez A; Cesar D; Abe K; Hanley MB; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK
    J Infect Dis; 2002 Feb; 185(3):315-23. PubMed ID: 11807713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
    Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
    J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.
    Albuquerque AS; Foxall RB; Cortesão CS; Soares RS; Doroana M; Ribeiro A; Lucas M; Antunes F; Victorino RM; Sousa AE
    Clin Immunol; 2007 Oct; 125(1):67-75. PubMed ID: 17692571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression.
    Papasavvas E; Sandberg JK; Rutstein R; Moore EC; Mackiewicz A; Thiel B; Pistilli M; June RR; Jordan KA; Gross R; Maino VC; Nixon DF; Montaner LJ
    J Infect Dis; 2003 Sep; 188(6):873-82. PubMed ID: 12964119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation.
    Benito JM; Lopez M; Lozano S; Ballesteros C; Capa L; Martinez P; Gonzalez-Lahoz J; Soriano V
    J Infect Dis; 2005 Dec; 192(12):2142-6. PubMed ID: 16288380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy.
    Wellons MF; Ottinger JS; Weinhold KJ; Gryszowka V; Sanders LL; Edwards LJ; Gooding ME; Thomasch JR; Bartlett JA
    J Infect Dis; 2001 May; 183(10):1522-5. PubMed ID: 11319689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.
    Deeks SG; Martin JN; Sinclair E; Harris J; Neilands TB; Maecker HT; Hagos E; Wrin T; Petropoulos CJ; Bredt B; McCune JM
    J Infect Dis; 2004 Jan; 189(2):312-21. PubMed ID: 14722897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
    J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death.
    Lecossier D; Bouchonnet F; Schneider P; Clavel F; Hance AJ;
    J Infect Dis; 2001 Apr; 183(7):1009-16. PubMed ID: 11237824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
    J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA; Hartman KE; Dragileva E; Dondero M; Gebretsadik T; Shintani A; Peiperl L; Valentine F; Kalams SA
    J Infect Dis; 2006 Sep; 194(5):661-5. PubMed ID: 16897665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity.
    Solomon A; Cameron PU; Bailey M; Dunne AL; Crowe SM; Hoy JF; Lewin SR
    J Infect Dis; 2003 Jun; 187(12):1915-23. PubMed ID: 12792868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.